3.51
-0.01 (-0.28%)
| Previous Close | 3.52 |
| Open | 3.52 |
| Volume | 199,024 |
| Avg. Volume (3M) | 1,253,304 |
| Market Cap | 126,669,584 |
| Price / Sales | 563.62 |
| Price / Book | 17.48 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 |
| Diluted EPS (TTM) | -1.97 |
| Total Debt/Equity (MRQ) | 9.76% |
| Current Ratio (MRQ) | 7.48 |
| Operating Cash Flow (TTM) | -53.59 M |
| Levered Free Cash Flow (TTM) | -32.40 M |
| Return on Assets (TTM) | -57.90% |
| Return on Equity (TTM) | -102.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Immuneering Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.75 |
|
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 24.12% |
| % Held by Institutions | 12.55% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Southport Management, L.L.C. | 31 Mar 2025 | 245,000 |
| Tidemark, Llc | 31 Mar 2025 | 44,400 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Oppenheimer, 754.70%) | Buy |
| Median | 15.50 (341.60%) | |
| Low | 11.00 (HC Wainwright & Co., 213.39%) | Buy |
| 11.00 (Needham, 213.39%) | Buy | |
| Average | 18.00 (412.82%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 7.84 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 30 Sep 2025 | 11.00 (213.39%) | Buy | 7.76 |
| Chardan Capital | 26 Sep 2025 | 20.00 (469.80%) | Buy | 7.76 |
| 14 Aug 2025 | 13.00 (270.37%) | Buy | 3.04 | |
| Oppenheimer | 25 Sep 2025 | 30.00 (754.70%) | Buy | 8.00 |
| Needham | 15 Sep 2025 | 11.00 (213.39%) | Buy | 7.86 |
| 26 Aug 2025 | 8.00 (127.92%) | Buy | 5.92 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |